Guardant Well being buys Israeli co MetaSight Diagnostics

US biotech firm Guardant Well being (Nasdaq: GH) has acquired Israeli exact liquid biopsy firm MetaSight Diagnostics for an instantaneous cost of $59 million and an extra $90 million in milestone funds. The acquisition was revealed in Guardant Well being’s fourth quarter outcomes. The milestone funds embody receiving regulatory approvals and gross sales thresholds. The corporate has developed assessments for correct early prognosis of most cancers that might price only some {dollars}.

MetaSight was based by Prof. Tomer Shlomi from the Technion along with aMoon Fund as a part of the aMoon Velocity program. The corporate makes use of multiomics applied sciences, to investigate cells utilizing totally different approaches, and mixing data with AI, to diagnose colon most cancers and metabolic issues in liver perform. The know-how is within the scientific trial stage.

The corporate developed the know-how primarily based on the Maccabi Well being Fund database.

The exit is modest however gives quick and good-looking returns for aMoon.. MetaSight was based in 2020 and has raised $20 million so far. Amongst its buyers are the US fund ARC and Saban Ventures. The corporate has workplaces in Rehovot that may turn out to be Guardant’s first improvement web site in Israel.

Dr. Yaron Daniely, who leads the aMoon Velocity program, tells “Globes,” “Guardant is a number one firm within the subject of most cancers prognosis utilizing superior strategies. Their market worth is about $13.7 billion they usually recorded income of a couple of billion {dollars} this 12 months.”

Discovered a typical language

How did the connection with the corporate come about?

“Guardant acknowledged the corporate’s benefits after we introduced our assessments at conferences that allow fast prognosis at costs of some {dollars} per check. They talked about of their convention name that that they had reviewed dozens of firms within the subject and selected our know-how from them.”

“We additionally selected them,” provides Dr. Daniely, “We acquired inquiries from a number of firms. With Guardant, we discovered widespread floor. The corporate’s cofounders and co-CEOs Helmy Eltoukhy and AmirAli Talasaz, are former Iranians, so there was a cultural connection between us. They based the corporate in 2012 and nonetheless function it with an entrepreneurial strategy. They significantly worth the corporate’s staff in Israel, and for the reason that acquisition, they’ve employed staff and expanded the laboratory. That is their first improvement heart not solely in Israel, however that is the primary time they’ve exterior the US.”

Nevertheless, Danieli says with a smile: “That does not imply that the negotiations had been straightforward.”

How was the corporate based?

“Prof. Shlomi approached us after creating a way to considerably scale back the price and pace up diagnostics utilizing a mass spectrometer. This technique allowed us to diagnose samples at very excessive resolutions. We teamed up with Maccabi and created a database of almost one million samples coded utilizing the MetaSight technique. Based mostly on this, we developed the colon most cancers check.

“The check is about two to 3 years away from finishing scientific trials, and if these are profitable, then the extra quantity can be paid within the deal.”

Printed by Globes, Israel enterprise information – en.globes.co.il – on February 21, 2026.